The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Hepatitis C Vaccines: Preclinical To Clinical Development
Funder
National Health and Medical Research Council
Funding Amount
$474,244.00
Summary
Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the p ....Hepatitis C is one of the most common notifiable infectious diseases in Australia with 200,000 infected individuals and 10,000 new infections each year. Treatments currently available for hepatitis C are effective but also associated with significant side effects and expensive. The economic and health burden of hepatitis C infection and the high costs of emerging antiviral therapies makes the development of an effective vaccine for HCV imperative. This project aims to develop a vaccine for the prevention of hepatitis C infection.Read moreRead less
The growing momentum towards elimination of malaria and the need to control of drug-resistant parasites means that new drugs and vaccines are needed. In this Fellowship I will use the human malaria challenge system that I have developed to test whether new drugs and vaccines for malaria are working sufficiently well to justify their full development. In this system healthy volunteers are deliberately infected with malaria and then cured before they become unwell.
Immunopathogenesis And Manipulation Of The HIV Reservoir
Funder
National Health and Medical Research Council
Funding Amount
$494,732.00
Summary
Kelleher is a Clinical immunologist with a globally recognised, sustained track record of translational research which has impacted both on our understanding of HIV immunopathogenesis and on the way HIV infection is treated. He will conduct a series of studies that encompass basic scientific techniques through to pivotal pre-clinical and clinical studies that will provide a pathway towards control of HIV-infection without daily therapy.
Translational Research On Malignant Pleural Effusion And Pleural Infection
Funder
National Health and Medical Research Council
Funding Amount
$487,891.00
Summary
I am a leading researcher in pleural effusions (fluid build-up in the chest) from cancer and infection. I run a multicentre clinical trial team to answer important questions directly relevant to patient care, as well as a lab research group with proven record of discovery new treatment targets. This fellowship will capitalize on platforms I have built and determine best approach to remove effusions, understand etiologic roles of the fluid ultimately to find ways to stop fluid from forming.
I aim to understand the genetics of the epilepsies. Through detailed analysis of different types of epilepsy, and associated features such as intellectual disability and autism, I will describe new epilepsy syndromes, and together with gene discovery, implement novel targeted therapies. This translational program will transform clinical practice by informing diagnosis, prognostic and genetic counseling, and lead to targeted precision therapies to improve outcomes for each patient.
Limiting Tuberculosis Transmission And Improving The Care Of Affected Children
Funder
National Health and Medical Research Council
Funding Amount
$412,419.00
Summary
Tuberculosis (TB) is the biggest infectious disease killer on the planet. Drug-resistant TB poses a particular challenge in the Asia-Pacific region. My research will assist Australia to progress towards domestic TB elimination. It will improve the management of “difficult to treat” cases and help to safeguard the public against ongoing TB transmission. Work in neighbouring countries will help to contain the spread of drug-resistant TB and protect vulnerable young children.
Tackling Key Epidemiological And Basic Scientific Research Issues In Prion Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$401,109.00
Summary
Proposed Practitioner Fellowship research will simultaneously include epidemiological and basic scientific projects, emphasising human prion disease. Epidemiological research will involve large-scale studies to clarify genetic factors that influence susceptibility to developing prion disease, as well as clarify whether Alzheimer disease is transmissible, while basic scientific research will include determining the characteristics of the misfolded prion proteins causing neuronal disease.
Improving Prevention, Tracking And Treatment Of Major Human Bacterial Pathogens
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
This research fellowship will lead to a detailed understanding of the mechanisms by which bacteria become resistant to antibiotics and cause diseases, how bacterial pathogens evolve and spread in the Australian community, and will result in new understanding of the optimal treatment of bacterial diseases and identification of compounds for new antibiotic development.
This application will allow me to restructure my work to provide sufficient time to do full justice to the current and planned commitments of our Respiratory Research Group. Our research programme includes the immunopathology of chronic airway diseases; the epidemiology of respiratory disease (TAHS); clinical physiology technology to service these studies; respiratory clinical pharmacology; microbe-host interactions in CF and COPD; and EBM in chronic respiratory disease self-management .